search
Back to results

Dementia Risk and Dynamic Response to Exercise (DYNAMIC)

Primary Purpose

Alzheimer Disease 2 Due to Apoe4 Isoform, Healthy Aging

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Moderate Intensity Aerobic Exercise
Sponsored by
University of Kansas Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alzheimer Disease 2 Due to Apoe4 Isoform

Eligibility Criteria

65 Years - 85 Years (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 65-85
  • English speaking
  • Normal or corrected hearing or vision,
  • Without activity restrictions.

Exclusion Criteria:

  • Clinically significant cognitive or psychiatric illness,
  • Anti- coagulant use,
  • High cardiovascular risk without physician clearance for exercise,
  • Exercise-limiting musculoskeletal condition,
  • MRI contraindications

Sites / Locations

  • University of Kansas Alzheimer's Disease Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Exercise - apolipoprotein e4 carrier

Exercise - apolipoprotein e4 non-carrier

Arm Description

A single 15 minute bout of moderate intensity aerobic exercise for individuals with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.

A single 15 minute bout of moderate intensity aerobic exercise for individuals with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.

Outcomes

Primary Outcome Measures

Cerebral Blood Flow Area Under Curve
Cumulative cerebral blood flow measured by Arterial Spin Labeling MRI. The standard arterial spin labeling unit of measure is average milliliters per 100 grams of tissue per minute (mL/100g tissue/minute). For the present analysis, we summed perfusion over the entire acquisition period, 23.2 minutes, rather than averaging. Therefore the units are milliliters per 100 grams of tissue

Secondary Outcome Measures

Insulin-like Growth Factor-1 Change
Change in circulating Insulin-like Growth Factor-1 from pre-to-post exercise
Vascular Endothelial Growth Factor Change
Change in circulating Vascular Endothelial Growth Factor from pre-to-post exercise
Brain Derived Neurotrophic Factor Change
Change in circulating Brain Derived Neurotrophic Factor from pre-to-post exercise

Full Information

First Posted
July 2, 2019
Last Updated
May 2, 2022
Sponsor
University of Kansas Medical Center
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT04009629
Brief Title
Dementia Risk and Dynamic Response to Exercise
Acronym
DYNAMIC
Official Title
Dementia Risk and Dynamic Response to Exercise
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
October 25, 2019 (Actual)
Primary Completion Date
October 28, 2021 (Actual)
Study Completion Date
October 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Kansas Medical Center
Collaborators
National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Research suggests that physical exercise supports brain health and cognition as we age. The goal of this project is to examine the specific changes in brain blood flow and biological factors in the blood immediately after exercise in older adults who have the APOE4 gene, a genetic risk factor for developing Alzheimer's. Results from this study will help researchers and clinicians understand and measure changes in the body and brain as a function of exercise, and how those changes relate to Alzheimer's risk.
Detailed Description
The brain and cardiovascular system share common risk factors for age-related diseases such as hypertension, hypercholesterolemia, and genetics (e.g. APOE4). Because of this link, much work has focused on the role of cerebrovascular health in reducing dementia risk. Regular aerobic exercise has well-established benefits for cardiovascular health and has been repeatedly linked to better cognition, brain health, and lower risk of Alzheimer's disease (AD). Despite strong evidence for sustained cognitive and brain outcomes, the mechanisms relating aerobic exercise with brain health and cognition remain imprecisely defined. Amongst many potential mechanisms, cerebral blood flow (CBF) and blood-based biomarkers, such as neurotrophins, are promising targets for their shared association to brain and cardiovascular health. Prior investigations have largely attempted to measure change in these mechanisms under resting conditions after an extended exercise intervention with mixed and conflicting results. Further, studies have often not accounted for genetic differences that may blunt the effect of exercise. Unlike prior work, our innovative approach is to begin by characterizing the dynamic changes that result from an acute exercise challenge. A single bout of aerobic exercise temporarily increases CBF and prompts neurotrophin release. These transient changes ultimately drive long-term physiologic adaptation to exercise. Therefore, the study team will characterize the dynamic response to an acute, standardized bout of aerobic exercise in a group of nondemented older adults, comparing those who do and do not carry the APOE4 allele. The first aim will test if CBF response to an acute exercise challenge is blunted in APOE4 carriers. The second aim will similarly test the acute exercise response of blood-based biomarkers such as brain derived neurotrophic factor, insulin-like growth factor, and vascular endothelial growth factor in APOE4 carriers versus non-carriers. The study team expects that more accurately understanding the acute effects will provide valuable insight into how aerobic exercise supports cognitive function and brain health. Armed with this knowledge the field can optimize biomarker measurement for future exercise intervention randomized controlled trials, informing our long-term goal of identifying precision exercise prescription for AD prevention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease 2 Due to Apoe4 Isoform, Healthy Aging

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single visit, case-control study identified as an intervention due to the use of a single bout of aerobic exercise under NIH rules (grants.nih.gov/policy/clinical-trials/definition.htm)
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
61 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercise - apolipoprotein e4 carrier
Arm Type
Experimental
Arm Description
A single 15 minute bout of moderate intensity aerobic exercise for individuals with 1 or 2 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.
Arm Title
Exercise - apolipoprotein e4 non-carrier
Arm Type
Experimental
Arm Description
A single 15 minute bout of moderate intensity aerobic exercise for individuals with 0 copies of the APOE4 allele, the leading genetic risk factor for late-onset Alzheimer's dementia.
Intervention Type
Behavioral
Intervention Name(s)
Moderate Intensity Aerobic Exercise
Intervention Description
Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
Primary Outcome Measure Information:
Title
Cerebral Blood Flow Area Under Curve
Description
Cumulative cerebral blood flow measured by Arterial Spin Labeling MRI. The standard arterial spin labeling unit of measure is average milliliters per 100 grams of tissue per minute (mL/100g tissue/minute). For the present analysis, we summed perfusion over the entire acquisition period, 23.2 minutes, rather than averaging. Therefore the units are milliliters per 100 grams of tissue
Time Frame
~24 minutes
Secondary Outcome Measure Information:
Title
Insulin-like Growth Factor-1 Change
Description
Change in circulating Insulin-like Growth Factor-1 from pre-to-post exercise
Time Frame
Pre-to-post intervention (~15 minutes)
Title
Vascular Endothelial Growth Factor Change
Description
Change in circulating Vascular Endothelial Growth Factor from pre-to-post exercise
Time Frame
Pre-to-post intervention (~15 minutes)
Title
Brain Derived Neurotrophic Factor Change
Description
Change in circulating Brain Derived Neurotrophic Factor from pre-to-post exercise
Time Frame
Pre-to-post intervention (~15 minutes)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 65-85 English speaking Normal or corrected hearing or vision, Without activity restrictions. Exclusion Criteria: Clinically significant cognitive or psychiatric illness, Anti- coagulant use, High cardiovascular risk without physician clearance for exercise, Exercise-limiting musculoskeletal condition, MRI contraindications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric D Vidoni, PT, PHD
Organizational Affiliation
University of Kansas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kansas Alzheimer's Disease Center
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data may be shared with unaffiliated investigators after completion of data collection and a reasonable amount of analysis and dissemination time. Contact the PI for further information.
IPD Sharing Time Frame
Following a reasonable amount of analysis and dissemination time, the data will be available via request.
IPD Sharing Access Criteria
Following institutional limits and recommendations and subject to use agreements.
Citations:
PubMed Identifier
35802628
Citation
Vidoni ED, Morris JK, Palmer JA, Li Y, White D, Kueck PJ, John CS, Honea RA, Lepping RJ, Lee P, Mahnken JD, Martin LE, Billinger SA. Dementia risk and dynamic response to exercise: A non-randomized clinical trial. PLoS One. 2022 Jul 8;17(7):e0265860. doi: 10.1371/journal.pone.0265860. eCollection 2022.
Results Reference
derived
PubMed Identifier
34140586
Citation
White D, John CS, Kucera A, Truver B, Lepping RJ, Kueck PJ, Lee P, Martin L, Billinger SA, Burns JM, Morris JK, Vidoni ED. A methodology for an acute exercise clinical trial called dementia risk and dynamic response to exercise. Sci Rep. 2021 Jun 17;11(1):12776. doi: 10.1038/s41598-021-92177-0.
Results Reference
derived

Learn more about this trial

Dementia Risk and Dynamic Response to Exercise

We'll reach out to this number within 24 hrs